AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think (Enduring)

CABP CE Eligible

This session will highlight advances in three areas of platelet research; stabilization methods through lyophilization, iPSC ex-vivo production, and synthetic nanoparticle technology are converging and can lead to long-lived platelet-based therapies targeted to address specific related pathologies or expanded uses that cannot currently be supported because of the short shelf-life and limited platelet supply. Attendees will hear from the current leaders in those three efforts including the status of clinical trials, nonclinical animal studies, characterization and mechanism of action, and pathways to clinical trials targeting uses beyond treating thrombocytopenia and platelet related coagulopathies. Platelets participate in many physiological and pathological processes, including hemostasis, thrombosis, wound healing and cellular regeneration, endothelial maintenance, immune responses, inflammation, tumor progression, and metastasis. Development and discovery efforts extend beyond the treatment of thrombocytopenia or hemorrhage. Potential uses include drug delivery, wound healing, cellular regeneration, endothelial repair and maintenance, treatment of traumatic brain injury, and providing HLA-homologous or reduced products to overcome refractoriness or reduce the risk of alloimmunization. Current supply and storage constraints limit the ability to support these research efforts and guarantee adequate post approval supplies. Available inventories are inadequate for current routine and emergent clinical demand. The ARC indicated in January of 2024 that the US experienced critical shortages caused by the lowest number of donors volunteering than in the last 20 years. A recent study simulating mass casualty incidents (MCIs) of 50-200 patients indicated that of the 16 Level 1 trauma centers participating none had enough platelets available to treat more than 4 patients at the recommended ratio (1.1.1). Near term solutions include extending cold stored platelets to 14 days, cryopreservation at -65°C, emergency LTOWB collections or increasing LTOWB inventory levels.